rs144681140
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_001243279.3(ACSF3):c.1406G>A(p.Arg469Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00631 in 1,614,082 control chromosomes in the GnomAD database, including 39 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. R469R) has been classified as Likely benign.
Frequency
Consequence
NM_001243279.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ACSF3 | NM_001243279.3 | c.1406G>A | p.Arg469Gln | missense_variant | 9/11 | ENST00000614302.5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ACSF3 | ENST00000614302.5 | c.1406G>A | p.Arg469Gln | missense_variant | 9/11 | 5 | NM_001243279.3 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.00467 AC: 711AN: 152168Hom.: 1 Cov.: 33
GnomAD3 exomes AF: 0.00431 AC: 1084AN: 251230Hom.: 3 AF XY: 0.00436 AC XY: 592AN XY: 135828
GnomAD4 exome AF: 0.00648 AC: 9476AN: 1461796Hom.: 38 Cov.: 32 AF XY: 0.00637 AC XY: 4635AN XY: 727192
GnomAD4 genome ? AF: 0.00467 AC: 711AN: 152286Hom.: 1 Cov.: 33 AF XY: 0.00443 AC XY: 330AN XY: 74456
ClinVar
Submissions by phenotype
Combined malonic and methylmalonic acidemia Uncertain:3Benign:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | May 01, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 26, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 22, 2023 | The ACSF3 c.1406G>A; p.Arg469Gln variant (rs144681140), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 203601). This variant is found in the general population with an overall allele frequency of 0.45% (1271/282590 alleles, including 3 homozygotes) in the Genome Aggregation Database. The arginine at codon 469 is weakly conserved, and computational analyses predict that this variant is neutral (REVEL: 0.114). While the high population frequency suggests that this is likely a benign variant, given the lack of clinical and functional data, the significance of this variant is uncertain at this time. - |
Likely benign, criteria provided, single submitter | clinical testing | Invitae | Jan 31, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 17, 2017 | The R469Q variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to ourknowledge. The R469Q variant is observed in 425/66442 (0.64%) alleles from individuals of European backgroundincluding one homozygote (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). TheR469Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as theseresidues differ in some properties. This substitution occurs at a position that is not conserved. In silico analysis isinconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Insummary, based on the currently available information, it is unclear whether this variant is a pathogenic variant or arare benign variant. - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 21, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
ACSF3-related disorder Benign:1
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 19, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2023 | ACSF3: BP4, BS2 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at